Table 2 Description of cases with moderate severity (PSS2), high severity (PSS3), and fatal outcome (PSS4).
# | Sex, age (y.o.) | Exposure | Insecticide | Severity | Symptoms |
|---|---|---|---|---|---|
1 | F, 0–4 | Indirect inhalation immediately following spray treatment of a room | Unspecified | PSS2 | Convulsive seizure |
2 | M, 0–4 | Direct inhalation during treatment | Pyrethroid | PSS2 | Convulsive seizure |
3 | F, 5–9 | Indirect exposure following treatment of a room | Unspecified | PSS2 | Convulsive seizure |
4 | M, 5–9 | Phosphine inhalation the night after powdering the insecticide in a room | Banned aluminium phosphide | PSS3 | Myocarditis |
5 | M, 5–9 | Phosphine inhalation the night after powdering the insecticide in a room | Banned aluminium phosphide | PSS4 | Myocarditis |
6 | F, 10–14 | Indirect inhalation and skin absorption while sleeping on a treated mattress | Banned organophosphate | PSS2 | Anticholinesterase syndrome |
7 | F, 20–24 | Phosphine inhalation the night after powdering the insecticide in a room | Banned aluminium phosphide | PSS2 | Prolonged vomiting |
8 | F, 20–24 | Direct inhalation during treatment | Pyrethroid spray | PSS2 | Dyspnea and prolonged coughing |
9 | F, 25–29 | Indirect exposure of product the night following treatment of a room | Unspecified | PSS2 | Prolonged vomiting |
10 | F, 40–44 | Direct inhalation during treatment | Diatomaceous earth | PSS2 | Asthma attack |
11 | F, 45–49 | Five days of indirect exposure following treatment of a room including mattresses | Unspecified | PSS2 | Prolonged diarrhea, paresthesia, tremors |
12 | F, 50–54 | Direct inhalation | Pyrethroid fogger | PSS3 | Respiratory distress |